CL2015000945A1 - Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa. - Google Patents
Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa.Info
- Publication number
- CL2015000945A1 CL2015000945A1 CL2015000945A CL2015000945A CL2015000945A1 CL 2015000945 A1 CL2015000945 A1 CL 2015000945A1 CL 2015000945 A CL2015000945 A CL 2015000945A CL 2015000945 A CL2015000945 A CL 2015000945A CL 2015000945 A1 CL2015000945 A1 CL 2015000945A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- gammat
- ror
- epoch
- crohn
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 208000011231 Crohn disease Diseases 0.000 title 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 102000006255 nuclear receptors Human genes 0.000 title 1
- 108020004017 nuclear receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010039073 rheumatoid arthritis Diseases 0.000 title 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714419P | 2012-10-16 | 2012-10-16 | |
| US201261725528P | 2012-11-13 | 2012-11-13 | |
| US201361782257P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000945A1 true CL2015000945A1 (es) | 2015-08-28 |
Family
ID=49546611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000945A CL2015000945A1 (es) | 2012-10-16 | 2015-04-15 | Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa. |
Country Status (38)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860099A1 (en) * | 2012-02-13 | 2013-08-22 | Johannes Aebi | Imidazolylketone derivatives asd aldosterone synthase inhibitors |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| DK2970283T3 (da) | 2013-03-14 | 2021-01-25 | Boehringer Ingelheim Int | Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c |
| JP6294953B2 (ja) | 2013-03-14 | 2018-03-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節物質 |
| ES2689526T3 (es) | 2013-03-14 | 2018-11-14 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| WO2015035278A1 (en) * | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | RORγ MODULATORS |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) * | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9624225B2 (en) * | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
| CA2927153A1 (en) * | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
| KR20160068948A (ko) * | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyt의 이차 알코올 퀴놀리닐 조절제 |
| US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US10555941B2 (en) * | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| CN107001342B (zh) * | 2014-05-28 | 2020-02-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
| ES2886641T3 (es) | 2014-08-11 | 2021-12-20 | Angion Biomedica Corp | Inhibidores de citocromo P450 y sus usos |
| EP3191492B1 (en) | 2014-09-12 | 2019-01-09 | Janssen Pharmaceutica NV | P2x7 modulators |
| WO2016039983A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| US10287282B2 (en) | 2014-12-31 | 2019-05-14 | Angion Biomedica Corp. | Methods and agents for treating disease |
| CN113164459B (zh) | 2018-09-28 | 2024-09-03 | 詹森药业有限公司 | 单酰基甘油脂肪酶调节剂 |
| CA3111309A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| TW202118751A (zh) * | 2019-10-31 | 2021-05-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | RORγ調節劑的酸加成鹽 |
| CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| IL297675A (en) | 2020-04-30 | 2022-12-01 | Idorsia Pharmaceuticals Ltd | History of aztidine-3-ylmethanol as ccr6 receptor modulators |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| CN112939974B (zh) * | 2021-03-11 | 2023-10-20 | 中山大学 | 一种氮杂苯并薁衍生物的制备方法 |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| JP2024539987A (ja) | 2021-10-26 | 2024-10-31 | イドルシア・ファーマシューティカルズ・リミテッド | Ｃｃｒ６受容体調節剤 |
| CA3236396A1 (en) | 2021-10-28 | 2023-05-04 | Oliver Allemann | Ccr6 receptor modulators |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472859A (en) | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
| JPS4826772Y1 (enExample) | 1969-04-04 | 1973-08-06 | ||
| DE3276432D1 (en) | 1981-03-24 | 1987-07-02 | Ciba Geigy Ag | Acyl quinolinone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use |
| US4910327A (en) | 1982-05-25 | 1990-03-20 | American Cyanamid Company | Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid: dialkyl 3-(substituted)phenylaminobut-2-ene-dioates and methods for the preparation thereof |
| US4656283A (en) | 1982-05-25 | 1987-04-07 | American Cyanamid Company | Alkyl esters of substituted 2-methyl-3-quinolinecarboxylic acid and quinoline-2,3-dicarboxylic acid |
| US4710507A (en) | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| FR2634483B2 (fr) | 1987-12-29 | 1994-03-04 | Esteve Labor Dr | Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments |
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5478832A (en) | 1992-05-08 | 1995-12-26 | The Green Cross Corporation | Quinoline compounds |
| JPH0826772A (ja) | 1994-07-22 | 1996-01-30 | Sony Corp | 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法 |
| DE69512495T2 (de) | 1994-10-27 | 2000-02-03 | Asahi Glass Co. Ltd., Tokio/Tokyo | Verfahren zur Herstellung von Chinolin-2-yl-benzoesäure |
| GB9523267D0 (en) | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| EE03484B1 (et) | 1995-12-08 | 2001-08-15 | Janssen Pharmaceutica N.V. | Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine |
| JP2000511532A (ja) | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
| DK0988038T3 (da) * | 1997-06-02 | 2002-12-02 | Janssen Pharmaceutica Nv | Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation |
| JP2001526265A (ja) | 1997-12-22 | 2001-12-18 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド |
| FR2776388B1 (fr) | 1998-03-20 | 2006-04-28 | Lipha | Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose |
| US6399629B1 (en) | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| CA2336624C (en) | 1998-07-06 | 2008-10-21 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties |
| HRP20000904A2 (en) * | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| JP2000169451A (ja) | 1998-09-30 | 2000-06-20 | Kyorin Pharmaceut Co Ltd | ６，７―ジ置換キノリンカルボン酸誘導体とその付加塩及びそれらの製造方法 |
| HU229404B1 (en) | 1998-12-23 | 2013-12-30 | Janssen Pharmaceutica Nv | 1,2-annelated quinoline derivatives |
| US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| ID29584A (id) | 1999-02-11 | 2001-09-06 | Pfizer Prod Inc | Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker |
| ES2212971T3 (es) | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
| AU2001233726A1 (en) | 2000-02-04 | 2001-08-14 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating breast cancer |
| CA2397558A1 (en) | 2000-02-24 | 2001-08-30 | Janssen Pharmaceutica N.V. | Dosing regimen |
| AU2001252147A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations |
| CA2397657A1 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| JP2003525237A (ja) | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
| WO2001064196A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| WO2001064198A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| WO2001064195A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| AU2001246478A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with taxane compounds |
| EP1261348A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| AU2001244166A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| EP1261341A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| EP1267929A2 (en) | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| US6844357B2 (en) | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
| US6525049B2 (en) | 2000-07-05 | 2003-02-25 | Pharmacia & Upjohn Company | Pyrroloquinolones as antiviral agents |
| DE60105614T2 (de) | 2000-07-12 | 2005-10-06 | Pharmacia & Upjohn Co., Kalamazoo | Oxazinochinolone für die behandlung viraler infektionen |
| US6624159B2 (en) | 2000-07-12 | 2003-09-23 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| AU2001293826A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| JP4974438B2 (ja) | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体 |
| AU2001293835A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| EA007464B1 (ru) | 2000-10-02 | 2006-10-27 | Янссен Фармацевтика Н.В. | Антагонисты метаботропных рецепторов глутамата |
| ATE323490T1 (de) | 2000-11-28 | 2006-05-15 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung |
| EP1347966B1 (en) | 2000-12-27 | 2006-03-08 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| EP1365763B1 (en) | 2001-02-15 | 2008-11-26 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| EP1363887A1 (en) | 2001-03-01 | 2003-11-26 | PHARMACIA & UPJOHN COMPANY | Substituted quinolinecarboxamides as antiviral agents |
| US20040157773A1 (en) | 2001-04-25 | 2004-08-12 | End David William | Farnesyl protein transferase inhibitors for treating cachexia |
| EP1412367A4 (en) | 2001-06-21 | 2006-05-03 | Ariad Pharma Inc | NEW CHINOLINE AND ITS USE |
| EP1456208A1 (en) | 2001-12-20 | 2004-09-15 | PHARMACIA & UPJOHN COMPANY | Pyridoquinoxaline antivirals |
| WO2003053971A1 (en) | 2001-12-20 | 2003-07-03 | Pharmacia & Upjohn Company | Pyridoquinoxaline antivirals |
| PL218788B1 (pl) | 2002-03-29 | 2015-01-30 | Janssen Pharmaceutica Nv | Znakowane radioaktywnie pochodne chinoliny i jej zastosowanie |
| AU2003257822A1 (en) | 2002-08-13 | 2004-04-30 | Shionogi And Co., Ltd. | Heterocyclic compound having hiv integrase inhibitory activity |
| WO2004019932A1 (en) | 2002-08-30 | 2004-03-11 | Pharmacia & Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| GB0222516D0 (en) | 2002-09-27 | 2002-11-06 | Karobio Ab | Novel compounds |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US7855207B2 (en) | 2003-11-20 | 2010-12-21 | Janssen Pharmaceutica, Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors |
| UA89618C2 (ru) | 2003-12-05 | 2010-02-25 | Янссен Фармацевтика Н.В. | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы |
| EA010592B1 (ru) | 2003-12-10 | 2008-10-30 | Янссен Фармацевтика Н.В. | 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы |
| SV2005001973A (es) | 2003-12-12 | 2005-11-04 | Wyeth Corp | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) |
| WO2005070430A1 (en) | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Quinoline derivatives and use thereof as mycobacterial inhibitors |
| ES2306098T3 (es) | 2004-01-29 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de quinolina para uso como inhibidores de micobacterias. |
| JP2005225250A (ja) | 2004-02-10 | 2005-08-25 | Murakami Corp | 車載用監視装置 |
| CA2569826C (en) | 2004-06-30 | 2013-07-16 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| CA2574095C (en) | 2004-08-04 | 2013-05-21 | Meiji Seika Kaisha, Ltd. | Quinoline derivatives and insecticide comprising thereof as active ingredient |
| KR100686531B1 (ko) | 2004-08-31 | 2007-02-23 | 한국화학연구원 | 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법 |
| WO2006052718A2 (en) | 2004-11-05 | 2006-05-18 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibitors for treating sepsis |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2855B1 (en) | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| WO2007088978A1 (ja) | 2006-02-03 | 2007-08-09 | Meiji Seika Kaisha, Ltd. | 新規キノリン誘導体およびこれを有効成分として含有する農園芸用殺菌剤 |
| US8389739B1 (en) | 2006-10-05 | 2013-03-05 | Orphagen Pharmaceuticals | Modulators of retinoid-related orphan receptor gamma |
| EA016527B1 (ru) | 2006-10-23 | 2012-05-30 | ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. | Триазолопиридазиновые модуляторы протеинкиназ |
| JO3271B1 (ar) | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US20100184803A1 (en) | 2007-03-09 | 2010-07-22 | Link Medicine Corporation | Treatment of Lysosomal Storage Diseases |
| WO2008144767A1 (en) | 2007-05-21 | 2008-11-27 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
| CN101143845B (zh) | 2007-10-15 | 2010-08-25 | 中国药科大学 | 取代喹啉甲酰胍衍生物、其制备方法及其医药用途 |
| WO2009091735A1 (en) | 2008-01-18 | 2009-07-23 | Allergan.Inc | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
| WO2009098576A1 (en) | 2008-02-05 | 2009-08-13 | Pfizer Inc. | Pyridinyl amides for the treatment of cns and metabolic disorders |
| BRPI0912604A2 (pt) | 2008-05-13 | 2019-09-10 | Allergan Inc | quinolinilmetilimidazóis como agentes terapêuticos |
| WO2010068296A1 (en) | 2008-12-11 | 2010-06-17 | Stiefel Laboratories, Inc. | Piperazine carboxamidines as antimicrobial agents |
| WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| CN101899011B (zh) | 2009-05-26 | 2013-01-16 | 北京大学 | 氨基二硫代甲酸酯类化合物、其制备方法和应用 |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| EP2368886A1 (en) | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| WO2011112264A1 (en) | 2010-03-11 | 2011-09-15 | New York University | Compounds as rorϒt modulators and uses thereof |
| WO2011130707A2 (en) | 2010-04-15 | 2011-10-20 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
| CA2816753A1 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases |
| US11179500B2 (en) | 2011-02-24 | 2021-11-23 | Emory University | JAB1 inhibitory compositions for ossification and methods related thereto |
| CN103619824B (zh) | 2011-04-28 | 2015-09-09 | 日本烟草产业株式会社 | 酰胺化合物及其药物用途 |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| EP2800745B1 (en) | 2011-12-02 | 2020-02-12 | Phenex Pharmaceuticals AG | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
-
2013
- 2013-10-15 PE PE2015000491A patent/PE20150778A1/es active IP Right Grant
- 2013-10-15 EP EP13786564.8A patent/EP2909192B1/en active Active
- 2013-10-15 EA EA201590736A patent/EA026415B1/ru unknown
- 2013-10-15 MX MX2015004783A patent/MX358508B/es active IP Right Grant
- 2013-10-15 MY MYPI2015701186A patent/MY189505A/en unknown
- 2013-10-15 BR BR112015008308A patent/BR112015008308A2/pt not_active Application Discontinuation
- 2013-10-15 HU HUE13786564A patent/HUE035335T2/en unknown
- 2013-10-15 SG SG11201502369XA patent/SG11201502369XA/en unknown
- 2013-10-15 UY UY0001035084A patent/UY35084A/es unknown
- 2013-10-15 CN CN201380065903.1A patent/CN105209453B/zh not_active Expired - Fee Related
- 2013-10-15 LT LTEP13786564.8T patent/LT2909192T/lt unknown
- 2013-10-15 HR HRP20171082TT patent/HRP20171082T1/hr unknown
- 2013-10-15 AR ARP130103735A patent/AR093017A1/es unknown
- 2013-10-15 KR KR1020157012838A patent/KR20150070347A/ko not_active Abandoned
- 2013-10-15 AU AU2013331496A patent/AU2013331496B2/en not_active Ceased
- 2013-10-15 NZ NZ706775A patent/NZ706775A/en not_active IP Right Cessation
- 2013-10-15 SM SM20170347T patent/SMT201700347T1/it unknown
- 2013-10-15 ME MEP-2017-151A patent/ME02794B/me unknown
- 2013-10-15 CA CA2888210A patent/CA2888210C/en not_active Expired - Fee Related
- 2013-10-15 PT PT137865648T patent/PT2909192T/pt unknown
- 2013-10-15 PL PL13786564T patent/PL2909192T3/pl unknown
- 2013-10-15 JP JP2015537769A patent/JP6466335B2/ja not_active Expired - Fee Related
- 2013-10-15 SI SI201330702T patent/SI2909192T1/sl unknown
- 2013-10-15 TW TW102137062A patent/TWI606045B/zh not_active IP Right Cessation
- 2013-10-15 RS RS20170741A patent/RS56283B1/sr unknown
- 2013-10-15 DK DK13786564.8T patent/DK2909192T3/en active
- 2013-10-15 ES ES13786564.8T patent/ES2632269T3/es active Active
- 2013-10-15 WO PCT/US2013/065013 patent/WO2014062658A1/en not_active Ceased
- 2013-10-15 US US14/053,653 patent/US9290476B2/en not_active Expired - Fee Related
-
2015
- 2015-03-22 IL IL237866A patent/IL237866B/en active IP Right Grant
- 2015-04-13 CR CR20150193A patent/CR20150193A/es unknown
- 2015-04-14 PH PH12015500817A patent/PH12015500817A1/en unknown
- 2015-04-15 NI NI201500053A patent/NI201500053A/es unknown
- 2015-04-15 GT GT201500093A patent/GT201500093A/es unknown
- 2015-04-15 EC ECIEPI201515022A patent/ECSP15015022A/es unknown
- 2015-04-15 CL CL2015000945A patent/CL2015000945A1/es unknown
- 2015-05-15 ZA ZA2015/03418A patent/ZA201503418B/en unknown
-
2017
- 2017-07-25 CY CY20171100793T patent/CY1119234T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000945A1 (es) | Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa. | |
| CL2015001249A1 (es) | Compuestos derivados de piridilo sustituidos con heteroarilo, como moduladores de cinasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como enfermedad de crohn, lupus eritematoso sistemico, esclerosis multiple, gota y artritis gotosa. | |
| CL2014002862A1 (es) | Compuestos derivados de benceno-1-sulfonamida, moduladores del receptor huerfano retinoideo gamma; composicion farmaceutica que los comprende; y su uso para el tratamiento de asma, bronquitis, fibrosis quistica, rinitis alergica, artritis reumatoide, artrosis, pancreatitis y colitis ulcerosa, entre otras enfermedades. | |
| CL2015000300A1 (es) | Compuestos derivados de pirroles y pirazoles sustituidos, moduladores del receptor nuclear huerfano ror gamma; composicion farmaceutica; uso en el tratamiento o profilaxis de enfermedades del sistema inmunitario tales como artritis reumatoide, lupus eritematoso, esclerosis multiple, epoc, entre otras. | |
| CL2015001268A1 (es) | Compuestos derivados de pirrolopirimidina, como inhibidores de quinasas; composicion farmaceutica que los comprende, util para el tratamiento de una enfermedad o condicion autoinmune tal como artritis reumatoide o lupus, y para el tratamiento de una enfermedad o condicion heteroinmune o inflamatoria. | |
| CL2014003277A1 (es) | Compuestos derivados heterociclicos sustituidos por carboxamida o sulfonamida, como moduladores para el receptor nuclear huerfano rorgama; composicion farmaceutica que los comprende, util para el tratamiento de artritis reumatoide, lupus eritematoso, psoriasis, esclerosis multiple, diabetes tipo 1, colitis ulcerosa, enfermedad pulmonar obstructiva cronica, entre otras. | |
| CL2016002421A1 (es) | Compuestos derivados de pteridina, como moduladores de ror gamma; composición farmacéutica que los comprende; y su uso para tratar una enfermedad autoinmune o trastorno alérgico tal como artritis reumatoide, psoriasis, lupus, esclerodermia, asma, rinitis alérgica, esclerosis múltiple, diabetes tipo i, enfermedad de crohn y colitis ulcerativa. | |
| CL2012002026A1 (es) | Compuestos derivados de amidas, inhibidores de hdac6; composicion farmaceutica que los comprende; kit farmaceutico;utiles en el tratamiento del cancer, artritis reumatoide, colitis ulcerativa, enfermedad de crohn, lupus eritematoso,sistemico, entre otras. | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| EP3390437C0 (en) | TARGETED DISRUPTION OF THE MHC CELL RECEPTOR | |
| CL2015000706A1 (es) | Compuestos derivados biciclicos conteniendo nitrogeno y sus sales; su proceso de obtencion; composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de estados patologicos renales, hepaticos, inflamatorios, del sistema nervioso, enfermedades fibroticas y rechazo agudo y cronico del trasplante de organos. | |
| CL2014002100A1 (es) | Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal. | |
| CL2017000271A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
| MX395458B (es) | Metodos novedosos | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| BR112014024941A2 (pt) | dispositivo de imagem de campo de visão amplo com capacidade de focalização ativa | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| CL2013002446A1 (es) | Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer. | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| DK3091919T3 (da) | Behandlingsintervaller til brug af sammensætninger, der indeholder energiabsorberende materialer til dermatologiske anvendelser | |
| CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. |